|
Gene: WFDC2 |
Gene summary for WFDC2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | WFDC2 | Gene ID | 10406 |
Gene name | WAP four-disulfide core domain 2 | |
Gene Alias | EDDM4 | |
Cytomap | 20q13.12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q14508 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10406 | WFDC2 | EEC-subject5 | Human | Endometrium | EEC | 2.88e-08 | 5.65e-01 | -0.249 |
10406 | WFDC2 | GSM5276934 | Human | Endometrium | EEC | 4.86e-16 | -5.62e-01 | -0.0913 |
10406 | WFDC2 | GSM5276935 | Human | Endometrium | EEC | 1.63e-58 | 9.85e-01 | -0.123 |
10406 | WFDC2 | GSM5276937 | Human | Endometrium | EEC | 1.88e-16 | -3.41e-01 | -0.0897 |
10406 | WFDC2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.60e-17 | 6.75e-01 | -0.1869 |
10406 | WFDC2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 7.63e-15 | 6.43e-01 | -0.1875 |
10406 | WFDC2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.70e-15 | 6.16e-01 | -0.1883 |
10406 | WFDC2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.05e-10 | 5.42e-01 | -0.1917 |
10406 | WFDC2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 9.30e-23 | 5.92e-01 | -0.1916 |
10406 | WFDC2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 8.09e-30 | 7.25e-01 | -0.1269 |
10406 | WFDC2 | LZE2T | Human | Esophagus | ESCC | 2.54e-12 | -9.66e-01 | 0.082 |
10406 | WFDC2 | LZE3D | Human | Esophagus | HGIN | 2.41e-02 | 2.61e+00 | 0.0668 |
10406 | WFDC2 | LZE4T | Human | Esophagus | ESCC | 2.57e-14 | -1.36e+00 | 0.0811 |
10406 | WFDC2 | LZE5T | Human | Esophagus | ESCC | 4.40e-16 | 4.19e+00 | 0.0514 |
10406 | WFDC2 | LZE7T | Human | Esophagus | ESCC | 6.72e-04 | -4.00e-01 | 0.0667 |
10406 | WFDC2 | LZE8T | Human | Esophagus | ESCC | 6.68e-24 | 2.98e+00 | 0.067 |
10406 | WFDC2 | LZE21D1 | Human | Esophagus | HGIN | 5.85e-07 | -1.40e+00 | 0.0632 |
10406 | WFDC2 | LZE24D1 | Human | Esophagus | HGIN | 2.04e-18 | 2.15e+00 | 0.054 |
10406 | WFDC2 | LZE22D3 | Human | Esophagus | HGIN | 2.21e-02 | 2.11e+00 | 0.0653 |
10406 | WFDC2 | LZE21T | Human | Esophagus | ESCC | 1.70e-08 | -1.35e+00 | 0.0655 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
GO:00104668 | Breast | Precancer | negative regulation of peptidase activity | 38/1080 | 262/18723 | 1.46e-07 | 7.82e-06 | 38 |
GO:00109519 | Breast | Precancer | negative regulation of endopeptidase activity | 37/1080 | 252/18723 | 1.55e-07 | 8.05e-06 | 37 |
GO:00197307 | Breast | Precancer | antimicrobial humoral response | 19/1080 | 122/18723 | 7.02e-05 | 1.40e-03 | 19 |
GO:005254714 | Breast | IDC | regulation of peptidase activity | 96/1434 | 461/18723 | 7.58e-20 | 6.15e-17 | 96 |
GO:005254814 | Breast | IDC | regulation of endopeptidase activity | 88/1434 | 432/18723 | 1.20e-17 | 4.85e-15 | 88 |
GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
GO:005134613 | Breast | IDC | negative regulation of hydrolase activity | 71/1434 | 379/18723 | 1.33e-12 | 2.90e-10 | 71 |
GO:001046613 | Breast | IDC | negative regulation of peptidase activity | 56/1434 | 262/18723 | 1.39e-12 | 2.92e-10 | 56 |
GO:001095112 | Breast | IDC | negative regulation of endopeptidase activity | 52/1434 | 252/18723 | 3.53e-11 | 5.57e-09 | 52 |
GO:001973011 | Breast | IDC | antimicrobial humoral response | 23/1434 | 122/18723 | 4.67e-05 | 1.04e-03 | 23 |
GO:00069596 | Breast | IDC | humoral immune response | 40/1434 | 317/18723 | 1.25e-03 | 1.33e-02 | 40 |
GO:005254723 | Breast | DCIS | regulation of peptidase activity | 88/1390 | 461/18723 | 1.18e-16 | 4.78e-14 | 88 |
GO:005254823 | Breast | DCIS | regulation of endopeptidase activity | 83/1390 | 432/18723 | 6.07e-16 | 2.15e-13 | 83 |
GO:004586123 | Breast | DCIS | negative regulation of proteolysis | 63/1390 | 351/18723 | 4.39e-11 | 6.06e-09 | 63 |
GO:005134623 | Breast | DCIS | negative regulation of hydrolase activity | 64/1390 | 379/18723 | 4.32e-10 | 4.80e-08 | 64 |
GO:001046622 | Breast | DCIS | negative regulation of peptidase activity | 49/1390 | 262/18723 | 1.54e-09 | 1.43e-07 | 49 |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WFDC2 | SNV | Missense_Mutation | c.253N>G | p.Ile85Val | p.I85V | Q14508 | protein_coding | tolerated(0.47) | benign(0.023) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
WFDC2 | SNV | Missense_Mutation | novel | c.265N>G | p.Gln89Glu | p.Q89E | Q14508 | protein_coding | tolerated(0.08) | benign(0.04) | TCGA-E2-A573-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
WFDC2 | SNV | Missense_Mutation | rs757484769 | c.152C>T | p.Ser51Leu | p.S51L | Q14508 | protein_coding | tolerated(0.08) | benign(0.081) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
WFDC2 | SNV | Missense_Mutation | c.37N>A | p.Leu13Ile | p.L13I | Q14508 | protein_coding | tolerated(0.11) | benign(0.017) | TCGA-BG-A18B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
WFDC2 | SNV | Missense_Mutation | novel | c.199N>A | p.Ala67Thr | p.A67T | Q14508 | protein_coding | tolerated(0.2) | benign(0.038) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WFDC2 | SNV | Missense_Mutation | novel | c.372C>A | p.Phe124Leu | p.F124L | Q14508 | protein_coding | tolerated(0.07) | benign(0.187) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
WFDC2 | SNV | Missense_Mutation | c.284N>T | p.Asp95Val | p.D95V | Q14508 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-44-7660-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Vaccine | recprame+as15 | PD | |
WFDC2 | SNV | Missense_Mutation | novel | c.231N>C | p.Glu77Asp | p.E77D | Q14508 | protein_coding | tolerated(0.19) | benign(0.348) | TCGA-KU-A66S-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |